New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against Both Planktonic Bacteria and Bacterial Biofilms
May 10 2022 - 8:00AM
Business Wire
Highlights
- In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log
reductions in planktonic (free-floating) bacteria and 4-log to
8-log reductions in biofilm bacteria (colonies of bacteria)
- XPERIENCE was shown to inhibit biofilm formation for up to five
hours after application
- Study published in The Journal of Arthroplasty
Next Science Limited (ASX:NXS) (Next Science / the
Company) is pleased to report that XPERIENCE™ No Rinse Solution
has been shown to have persistent efficacy against both planktonic
bacteria and bacterial biofilms in a new study published in The
Journal of Arthroplasty. The study, “A Novel Irrigant to Eliminate
Planktonic Bacteria and Eradicate Biofilm Superstructure With
Persistent Effect During Total Hip Arthroplasty,” also found that
XPERIENCE produced minimal cytotoxic effects to human tissue,
allowing the solution to remain in the body without need for
subsequent rinse. Additionally, XPERIENCE – cleared by the FDA for
U.S. sale in April 2021 – was shown to inhibit biofilm formation
for up to five hours after application.
Prosthetic joint infection (PJI) remains a significant burden in
total hip arthroplasty (THA) and total knee arthroplasty (TKA) in
the United States. Estimates indicate that, by 2030, the annual
hospital costs related to PJI of the hip and knee will be $1.85
billion.1 Interventions to reduce or prevent the occurrence of PJI
continue to be at the forefront of research efforts and commercial
development.
“The minimum standard of care for irrigation in orthopedic
surgical cases includes normal saline, but an increasing amount of
literature in recent years has suggested that different solutions
or additives may be needed to prevent PJI,” said orthopedic surgeon
Ravi K. Bashyal, MD, the study’s lead author. “Combatting
planktonic bacteria and the formation of biofilm is especially
important given the high negative consequence of developing a PJI
in the total joint arthroplasty setting.”
In the in vitro study, XPERIENCE demonstrated 4-log to 6-log
reductions in planktonic bacteria after five minutes, and 4-log to
8-log reductions in biofilm bacteria. Future research using
large-series in vivo data is necessary to further establish the
irrigant’s efficacy in reducing primary and recurrent surgical site
infections (SSIs). An estimated 1.5 million SSIs in the United
States each year2 contribute $3.3 billion to the cost of U.S.
healthcare.3
The study also found that XPERIENCE showed higher in vitro
antimicrobial efficacy than three other commercially available
adjuvants. The comparative treatments each reduced biofilm in all
bacterial strains tested by approximately 1-log or less when the
application times in their respective instructions for use were
followed. However, XPERIENCE reduced biofilm by approximately 3-log
to 8-log when used as directed.
About Next Science
Next Science is a medical technology company headquartered in
Sydney, Australia, with a research and development center in
Florida, USA. Established in 2012, the Company’s primary focus is
on the development and continued commercialization of products
powered by its proprietary XBIO Technology. For further information
visit: www.nextscience.com.
Forward looking statements
This announcement may contain forward looking statements which
may be identified by words such as “believes”, “considers”,
“could”, “estimates”, “expects”, “intends”, “may”, and other
similar words that involve risks and uncertainties. Such statements
are not guarantees of future performance and involve known and
unknown risks, uncertainties, assumptions and other important
factors, many of which are beyond the control of Next Science or
its Directors and management, and could cause Next Science’s actual
results and circumstances to differ materially from the results and
circumstances expressed or anticipated in these statements. The
Directors cannot and do not give any assurance that the results,
performance or achievements expressed or implied by the
forward-looking statements contained in this announcement will
actually occur and investors are cautioned not to place undue
reliance on these forward-looking statements.
1
Premkumar A., Kolin D.A., Farley K.X., et
al. “Projected Economic Burden of Periprosthetic Joint Infection of
the Hip and Knee in the United States.” J Arthroplasty,
2021;36(5):1484-1489 e1483.
2
Darouiche, R. (2019). “Surgical Site
Infections.” Retrieved from:
https://www.infectiousdiseaseadvisor.com/home/decision-support-in-medicine/
hospital-infection-control/surgical-site-infections
3
Zimlichman, E., et al. “Health
Care-Associated Infections. A Meta-Analysis of Costs and Financial
Impact on the US Health Care System.” JAMA Intern Med, 173(22):
(2013): 2039-46.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220510005529/en/
Judith Mitchell Managing Director, Next Science Limited Phone:
+61 2 9375 7989 Email: investorqueries@nextscience.com
Anthony Priwer Dalton Agency Phone: +1 615-515-4891 Email:
apriwer@daltonagency.com
Nexus Gold (TSXV:NXS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nexus Gold (TSXV:NXS)
Historical Stock Chart
From Oct 2023 to Oct 2024